XT
XTL Biopharmaceuticals Ltd.
XTLB · NASDAQ
$2.20 -4.34% (-$0.10)
1M -14.73%
Market Cap $22.5M
P/E Ratio -
Div. Yield -
ROE 31.28%
Bulios Fair Price
$2.05
6.8% downside
Current Price
$2.2
Undervalued Fair Value Overvalued
According to Bulios Fair Price, XTLB is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 49.90x
PEG N/A
P/E N/A
Growth
28 /100
Declining Book val. growth 0.63%
FCF growth N/A
EPS growth N/A
Profitability
11 /100
Weak Op. margin 481.60%
Gross margin 26.39%
FCF margin 0.00%
Quality
15 /100
Poor ROA 618.68%
ROIC 12,853.00%
Asset turnover 2.72x
Debt
0 /100
High Int. coverage -13.31x
Current ratio 0.40x
Debt/Assets N/A
Stability
41 /100
Moderate Profitable years 0
Beta 0.45x
EPS volatility N/A
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about XTLB
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Noam Band
Employees
10
Headquarters
Herzliya